Panel Discussion: Navigating Patient Selection & Eligibility in Europe to Ensure Timely Access to Cell Therapies
- Examine the complexities of trial design across oncology and autoimmune indications, including comorbidities, inpatient requirements, and overlapping recruitment efforts
- Discuss the readiness of Europe’s academic and healthcare ecosystems, from educating rheumatologists and haematologists to training medical staff in managing CAR-T related toxicities
- Highlight strategies to streamline patient identification and enrolment, including earlier eligibility assessments and addressing barriers such as hospital capacity and fragile patient timelines